Manufacturer record
Bioaltus Pharmaceuticals Pvt. Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
4 batches manufactured by Bioaltus Pharmaceuticals Pvt. Ltd (Himachal Pradesh) were declared Not of Standard Quality between March 2024 and May 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
4 records linked to Bioaltus Pharmaceuticals Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Rosuvastatin, Aspirin and Clopidogrel Capsules | SIBP25509Mfg 2025-08 · Exp 2027-07 | The sample does not conform to the claim with respect to Assay of Rosuvastatin and Aspirin.Assay | DTL JaipurState lab | May 2026 |
| VITACRINE LC (Alpha Lipoic Acid, Folic Acid, Methylcobalamin, Pyridoxine Hydrochloride & Vitamin D3 Tablets) | BD250297BMfg 2025-02 · Exp 2027-01 | Test for Disintegration onlyDisintegration | DTL, Bengaluru, KarnatakaState lab | Oct 2025 |
| Rosuvastatin 10 mg, Aspirin 150 mg and Clopidogrel 75 mg Capsules | SIBP24283Mfg 2024-06 · Exp 2026-05 | Assay for RosuvastatinAssay | DTL, Bengaluru, KarnatakaState lab | Oct 2025 |
| Telmisartan and Hydrochlorothiazide Tablets IP (Telverge H) | BD231669HMfg 2023-11 · Exp 2025-10 | Dissolution of HydrochlorothiazideDissolution | CDTL HyderabadCDSCO lab | Mar 2024 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.